Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Grand Pharmaceutical Group Limited
遠大醫藥集團有限公司*
(Incorporated in Bermuda with limited liability)
(Stock Code: 00512)

VOLUNTARY ANNOUNCEMENT

SIX OF THE GROUP'S PRODUCTS ARE SUCCESSFULLY INCLUDED IN THE NATIONAL REIMBURSEMENT DRUG CATALOG 2026, COMMERCIAL INSURANCE INNOVATIVE DRUG CATALOG AND OTHER INDUSTRY-RELATED LISTS

This announcement is made by the board of directors (the "**Board**") of Grand Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The Board is pleased to announce that the Group has a total of six products successfully included in the *National Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance Drug Catalog (2026)** (《國家基本醫療保險、生育保險和工傷保險藥品目錄(2026年)》, the "**National Reimbursement Drug Catalog**") and the *Commercial Health Insurance Innovative Drug Catalog (2026)** (《商業健康保險創新藥品目錄(2026年)》, the "**Commercial Insurance Innovative Drug Catalog**") issued by the National Healthcare Security Administration (NHSA) of the People's Republic of China, the *Recommended List of Drug Coverage for Commercial Health Insurance (First Edition)** (《商業健康保險藥品保障推薦清單(第一版)》, the "**Recommended List**") issued by the Insurance Association of China, or the *Drug Involved in the Cost Estimation of Commercial Health Insurance Coverage** (《商業健康保險保障成本測算涉及藥品》, the "**Cost List of Commercial Insurance Coverage**") issued by China Association of Actuaries recently.

These six products include: Yigantai® (Y-90 microsphere injection), which was successfully included in the Commercial Insurance Innovative Drug Catalog and Recommended List for the first time; Ryaltris® (olopatadine mometasone nasal spray), which was included in the National Reimbursement Drug Catalog for the first time; Enerzair® Breezhaler® (indacaterol acetate, glycopyrronium bromide and mometasone furoate powder for inhalation II), Atectura® Breezhaler® (indacaterol acetate and mometasone furoate powder for inhalation II, III) and Limeitong® (eplerenone tablets), which successfully renewed their inclusion in the National Reimbursement Drug Catalog; and Anweide® (carglumic acid dispersible tablets), which was included in the Cost List of Commercial Insurance Coverage for the first time.

Yigantai® has been successfully included in the Commercial Insurance Innovative Drug Catalog and Recommended List for the first time.

The Group's blockbuster, global innovative product, Yigantai® (Y-90 microsphere injection), is indicated for the treatment of patients with unresectable colorectal cancer liver metastases ("**mCRC**") who have failed standard therapies. Yigantai® is the world's first and only selective internal radiation therapy ("**SIRT**") product that approved by the United States Food and Drug Administration ("**FDA**") indicated for both unresectable hepatocellular carcinoma ("**HCC**") and mCRC. This product was approved for commercialization by the FDA and the European Medicines Agency (EMA) in 2002, and was approved for commercialization in China by the National Medical Products Administration (NMPA) in 2022. In July 2025, it was granted FDA approval for an additional indication, HCC, and in August of the same year, it received an expanded CE mark in Europe covering various types of liver cancer, thereby achieving comprehensive coverage in the treatment of unresectable liver cancer. Over the more than 20 years since its commercialization, it has been used by over 150,000 patients across more than 50 countries and regions worldwide. It is recommended by numerous authoritative domestic and international clinical guidelines, including the Barcelona Clinic Liver Cancer (BCLC), the National Comprehensive Cancer Network (NCCN), the European Society for Medical Oncology (ESMO) diagnosis of HCC, the European Association for the Study of the Liver (EASL) guidelines for HCC, the United Kingdom National Institute for Health and Care Excellence (NICE), and China Guidelines for the *Diagnosis and Treatment of Primary Liver Cancer** (《原發性肝癌診療指南》).

As the only SIRT product included in the Commercial Insurance Innovative Drug Catalog, and also included the *Recommended List of Drug Coverage for Commercial Health Insurance (First Edition)** (《商業健康保險藥品保障推薦清單（第一版）》) which issued by the Insurance Association of China for the first time, Yigantai® represents a significant milestone in the commercialization of the Group's radiopharmaceutical segment. This achievement marks a pivotal step in integrating the Group into the commercial health insurance ecosystem. By opening up diversified payment channels, this development not only helps alleviate the financial burden on patients and enhances the accessibility and market penetration of innovative radiopharmaceuticals, but also accelerates clinical adoption and the realization of commercial value. Furthermore, it underscores the high level of recognition from both national authorities and the industry regarding the value of radiopharmaceutical innovation, setting a valuable precedent for the market access and commercial expansion of the Group's future radiopharmaceutical products. Moving forward, the Group will continue to explore synergistic models between innovative drugs and commercial health insurance, further enriching its commercialization strategy and providing robust support for the high-quality development of its innovative drug business.

Ryaltris® has been successfully included in the National Reimbursement Drug Catalog for the first time.

Ryaltris® (olopatadine mometasone nasal spray) is a novel antihistamine and corticosteroid combination nasal spray for the treatment of moderate to severe seasonal allergic rhinitis ("**AR**") in adult and pediatric patients 6 years of age and older, and moderate to severe perennial AR in adult and pediatric patients 12 years of age and older. The product boasts three major advantages: strong initial efficacy, synergistic dual-ingredient formula for rapid symptom relief; the only compound nasal spray for allergic rhinitis in children aged 6 and above approved in China; and a pleasant taste that makes it easy to maintain. Authoritative clinical guidelines and expert consensus documents both domestically and internationally, such as the *Chinese*

*Guideline for Diagnosis and Treatment of Allergic Rhinitis (2022)** (《中國變應性鼻炎診斷和治療指南(2022 版)》), the *Clinical Consensus on Classification, Diagnosis and Intranasal Medication of Rhinitis (2019)** (《鼻炎分類和診斷及鼻腔用藥方案臨床共識（2019 版)》), and the *2019 ARIA Care pathways for allergen immunotherapy*, recommend intranasal antihistamines and intranasal corticosteroids as the first-line treatments for allergic rhinitis. As a combination formulation, Ryaltris® offers patients a more convenient and effective treatment option, further improving medication adherence, and providing a new therapeutic option for AR patients in China.

Enerzair® Breezhaler®, Atectura® Breezhaler® and Limeitong® renewed their inclusion in the National Reimbursement Drug Catalog.

Enerzair® Breezhaler® is the first triple compound inhalation preparation for asthma indications approved in China for the maintenance treatment of asthma in adults not adequately controlled with the maintenance combination treatment of long-acting beta2-adrenergic agonist ("**LABA**") and inhaled corticosteroid ("**ICS**"). The product has clear efficacy, is convenient to use, and has achieved breakthroughs in three aspects: (1) using an optimized drug combination of ICS, LABA and long-acting muscarinic receptor antagonist (LAMA), the three effective ingredients can provide synergy benefit, effectively improve the clinical symptoms and lung function of patients with moderate to severe asthma, and significantly reduce the risk of acute attacks; (2) dosing once a day, which significantly facilitates the patient and is expected to improve the compliance; (3) using the advanced Breezhaler® inhalation device, which is easy to operate, and provides patients with triple dosing confirmation as audible, tasteable, and visible, enhancing patients' confidence in medication.

Atectura® Breezhaler® is an innovative combination of ICS mometasone furoate and LABA indacaterol acetate for the maintenance treatment of adult and 12 years old above adolescent patients with asthma. Atectura® Breezhaler® also has the characteristics including "visible and controllable, precise inhalation, once a day" etc. It can significantly improve the lung function of patients and reduce the risk of acute attack, and is a new choice for optimal treatment of asthma patients.

Enerzair® Breezhaler® and Atectura® Breezhaler® have been both included in the *Chinese Expert Consensus on Standardized Inhaler Device Application in Stable Chronic Airway Diseases (2023)*, the *Chinese Expert Consensus on the Diagnosis and Management of Severe Asthma (2024)*, the *Guidelines for the Prevention and Management of Bronchial Asthma (2024)*, the *2025 Global Strategy for Asthma Management and Prevention* and other authoritative clinical guidelines and expert consensus documents both domestically and internationally.

Limeitong® (eplerenone tablets) is a new mineralocorticoid receptor antagonist ("**MRA**") drug. It can block heart disease and vascular damage caused by excessive activation of mineralocorticoid receptor ("**MR**") by binding to the MR. Compared with the first-generation MRA drug Spironolactone, eplerenone has higher MR selectivity and lower affinity for androgen receptor and progesterone receptor, so it has fewer side effects and is a safe and effective new generation of MRA drug.

In addition, Anweide® (carglumic acid dispersible tablets) has been included in the Cost List of Commercial Insurance Coverage which is compiled and published for the first time by China Association of Actuaries. This product is an orphan drug independently developed by the Group for the treatment of hyperammonemia in adults or children caused by N-acetylglutamate synthetase (NAGS) deficiency, Isovaleric acidemia (IVA), methylmalonic acidemia (MMA),

or propionic acidemia (PA). The inclusion this time marks a crucial step for the orphan drug Anweide® from "recognition of its clinical value" to "supported by pricing infrastructure at the payment end". It not only establishes a leading position for the product within the commercial health insurance payment framework, but also provides the Group with an important opportunity to establish first-mover recognition at the payment end, helping to improve product accessibility and market penetration, and accumulating valuable payment-end experience for the subsequent commercialization of its orphan disease pipeline.

The Group believes that the synergy between medical insurance and commercial insurance is an important measure taken by the nation to "ensure basic healthcare and promote innovation" and to strongly support the high-quality development of innovative drugs. The Group's six products, accessed through diverse pathways within the multi-tiered healthcare system, will not only improve patients' access to medication in relevant disease areas and effectively reduce the burden of treatment, but will also further accelerate market penetration and coverage, forming a virtuous cycle from the payment end to the clinical end, laying a solid foundation for long-term high-quality growth.

The Group always puts focus on the R&D of innovative products and advanced technologies. Adhering to a patient-centered and innovation-driven approach, the Group will continue to increase its investment in world-class innovative products and advanced technologies to meet unmet clinical needs and enrich its product pipeline and improve supply chain. The Group adopts the strategy of "global expansion and dual-cycle operation", forming a new pattern of domestic and international cycles that synergize with each other. In this way, the Group can make full use of its industrial advantages and R&D capabilities, to accelerate the commercialization process for innovative products and provide patients with more advanced and diverse treatment options globally.

Warning:

The production, sales and contributed profit of aforementioned products is subject to various factors such as market changes with uncertainty. Shareholders and prospective investors of the Company are advised to exercise caution when dealing in the securities of the Company.

Note: The English transliteration of the Chinese name(s) in this announcement is included for information purpose only, and should not be regarded as the official English name(s) of such Chinese name(s).

By order of the Board
Grand Pharmaceutical Group Limited
Chairman
Dr. Tang Weikun

Hong Kong, 15 November 2026

As at the date of this announcement, the Board comprises four executive directors, namely, Dr. Tang Weikun, Mr. Zhou Chao, Mr. Yang Guang and Ms. Lam Chit Yee Jessica, and four independent non-executive directors, namely, Ms. So Tosi Wan, Winnie, Dr. Xing Li Na, Dr. Pei Geng and Mr. Hu Yebi.

** For identification purpose only*